Putnam Investments’s ImmunityBio IBRX Stock Holding History

Putnam Investments’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$2.68M	Buy	+534,201	New	+$1.68M	﹤0.01%	688
2023 Q1	–	Sell	-171,939	Closed	-$872K	–	1172
2022 Q4	$872K	Sell	171,939 -92	-0.1%	-$505	﹤0.01%	855
2022 Q3	$855K	Sell	172,031 -3,119	-2%	-$14.2K	﹤0.01%	878
2022 Q2	$651K	Sell	175,150 -2,176	-1%	-$8.74K	﹤0.01%	907
2022 Q1	$995K	Buy	177,326 +88,028	+99%	+$540K	﹤0.01%	902
2021 Q4	$543K	Buy	+89,298	New	+$671K	﹤0.01%	955

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Putnam Investments's IBRX Position: Q4 2023 in Review

Putnam Investments opened a new position in ImmunityBio (IBRX) in Q4 2023: 534,201 shares worth $2.68M. The stake represents ﹤0.01% of the portfolio and ranks #688 among its holdings. This is a return to the name: Putnam Investments previously reported a position in IBRX as recently as Q4 2022.

Putnam Investments first reported a position in IBRX in Q4 2021 and has held it in 6 quarters since. 147 funds tracked by Wall St. Rank hold IBRX as of Q4 2023.

Putnam Investments held 534,201 shares of ImmunityBio worth $2.68M as of Q4 2023.
ImmunityBio was a new Putnam Investments position in Q4 2023.
ImmunityBio made up ﹤0.01% of Putnam Investments's portfolio in Q4 2023, its #688 holding.
Putnam Investments first reported a position in ImmunityBio in Q4 2021 and has held it in 6 quarters since.
147 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2023.

Based on Putnam Investments's 13F filing for Q4 2023, filed 14 Feb 2024.